Entrectinib effects and efficacy

EntrectinibIt is used to treat adults with non-small cell lung cancer that has spread to other parts of the body. Entrectinib is also used to treat certain types of solid tumors in adults and children 12 years and older that cannot be treated with surgery or have spread to other parts of the body and get worse after treatment with other chemotherapy drugs. Entrectinib belongs to the class of kinase inhibitor drugs . Entrectinib works by blocking the activity of abnormal proteins, which are signals for cancer cell reproduction. This helps prevent or slow down the spread of cancer cells.

Among those evaluable for efficacy (N = 161The data cutoff date is 2019 year 5month) , the objective response rate (ORR) is 67% (95% Confidence interval [CI]:59.3–74.3), alleviate The median duration (DoR) was 15.7 months (95% CI: 13.9–28.6), and median progression-free survival (PFS) was 15.7 months (95% CI: 11.0–21.1). This data shows that it is quite optimistic. Preclinical studies have shown that entrectinib can cross the blood-brain barrier. On this basis, entrectinib is considered to be able to target brain metastases and primary brain tumors. Entrectinib has a plasma half-life of 20-22 hours when administered orally, allowing for a once-daily continuous dosing regimen (in a Phase 1/2 trial, 600 mg daily was determined to be the maximum tolerated dose in adults). There are generic drugs in Laos, the officially marketed version, with government approval, the retail price of pharmaceuticals in Laos and ASEAN200mg90 tablets20000RMB, 100mg30A pillabout 6500yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.